---
title: "HilleVax (HLVX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/HLVX.US.md"
symbol: "HLVX.US"
name: "HilleVax"
industry: "生物技术"
---

# HilleVax (HLVX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |

## Company Profile

HilleVax, Inc.是一家临床阶段的生物制药公司，专注于在美国开发和商业化疫苗。该公司开发了 HIL-214，这是一种基于病毒样颗粒的疫苗候选者，旨在预防由诺如病毒感染引起的中度至重度急性肠胃炎。它与武田疫苗公司（Takeda Vaccines, Inc.）签订了许可协议，以开发和商业化 HIL-214 药品

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.46 | 251/605 | - | - | - |
| PB | 0.70 | 61/605 | 0.70 | 0.70 | 0.60 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.09 |
| Highest Target | 2.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/HLVX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/HLVX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/HLVX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.